
0 Comment(s) - Average Rating : N/A
Thursday November 19, 2009 12:37 AM PST
By M.E. Garza
Here's a closer look at the incredible trading activity for the two stocks we issued alerts on this week: Power3 Medical (OTC:PWRM) and Viking Systems (OTC:VKNG). Are the runs up done or is the table set for yet another push upwards?
0 Comment(s) - Average Rating : N/A
Wednesday November 18, 2009 2:14 AM PST
By M.E. Garza
Could PWRM easily become the next "Vermillion Dollar Baby?"
0 Comment(s) - Average Rating : N/A
Tuesday November 17, 2009 12:39 AM PST
By M.E. Garza
You can't go much further down than this. It looks like it's time to go higher from here.
0 Comment(s) - Average Rating : N/A
Tuesday November 17, 2009 12:24 AM PST
By M.E. Garza
Does this promising penny still have more room to run? You bet!
0 Comment(s) - Average Rating : N/A
Sunday November 15, 2009 5:23 PM PST
By M.E. Garza
It's rare to find a profitable small cap biotech company, much less one that has been flying under the radar screen and has so many positive features that can help propel its share price upward quickly.
0 Comment(s) - Average Rating : N/A
Sunday November 15, 2009 12:56 AM PST
By M.E. Garza
Some of the names on the list are small caps, but all of the companies are either biotechnology or pharmaceutical and they all meet other Index eligibility criteria.
0 Comment(s) - Average Rating : N/A
Thursday November 12, 2009 6:59 PM PST
By M.E. Garza
Accusations are heating up in the drama involving Hemispherx Biopharma, Inc (AMEX:HEB) and the law firms trying to go after the well capitalized company on behalf of investors.
0 Comment(s) - Average Rating : N/A
Thursday November 12, 2009 6:56 PM PST
By M.E. Garza
Is the management at CEL-SCI Corporation (AMEX:CVM) signaling that something big is in the works?
0 Comment(s) - Average Rating : N/A
Tuesday November 10, 2009 3:05 PM PST
By M.E. Garza
The results of a soon to be released study by Bioelectronics Corp. (OTC:BIEL) have set the table for an intriguing penny play in the coming days.
0 Comment(s) - Average Rating : N/A
Tuesday November 10, 2009 6:59 AM PST
By M.E. Garza
The stock should continue to climb steadily as Spectrum is currently conducting two Phase 3 clinical trials; with enrollment in both studies expected by the end of this year.